Chapter 5
The conversation took place during a panel at Biotech Showcase titled Engineering the Future: Advances in Cell and Gene Therapy. While the founders on stage were working across very different technologies, the discussion stayed focused on a shared, practical question. What actually makes cell and gene therapy work in patients.
Rather than framing the field around a single breakthrough or platform, the panel reflected how much the thinking has evolved. Progress today is less about finding the most powerful tool and more about choosing the right one for a specific disease.
Choosing the Right Biology for the Disease
One of the clearest themes was that there is no universal solution in cell and gene therapy. The emphasis was on understanding the disease first, then selecting the immune cell or genetic approach that actually makes sense in that context.
In complex solid tumors, especially those that suppress immune activity, coordinating a broader immune response can matter more than directing a single cell to attack a single target. In these settings, durability and breadth can be as important as potency.
Engineering was discussed as a way to improve decision making inside the therapy itself. “Cells can do things that no other modality is capable of doing,” one comment highlighted, referring to therapies designed to recognize when to act and when to stay quiet. This kind of built in judgment becomes critical in diseases where clean targets do not exist.
On the gene therapy side, the focus shifted away from cutting DNA and toward regulating it. “We don’t cut DNA. We use its binding power to regulate gene expression instead.” For many diseases, genes are present but misregulated. Adjusting how strongly they are expressed can be enough to restore function, without introducing the risks that come with permanent DNA changes.
Making Therapies Practical to Deliver
Beyond biology, the panel spent considerable time on execution. Cell and gene therapies are living products, which makes them expensive, fragile, and difficult to manufacture consistently. Automation and process improvements can help, but timing matters. “If you automate too soon and the agency tells you something needs to change, you end up rebuilding everything.” Clinical proof remains the first priority.
Regulatory engagement was discussed in a similarly pragmatic way. Transparency and early dialogue were emphasized over speed. That approach helped align expectations and move novel science into the clinic.
Questions around cost and reimbursement were approached without oversimplification. The panel acknowledged that these therapies are expensive, but emphasized that value is tied to impact. In diseases with few or no alternatives, where therapies can save lives or restore function, reimbursement tends to follow. In other settings, the bar is higher and should be.
What stood out across the discussion was the absence of exaggeration. The conversation was not about chasing attention or promising universal solutions. It was about execution, tradeoffs, and making decisions that reflect both biology and reality.
Founder’s Note
What stayed with me from this panel was how consistently the conversation returned to judgment rather than novelty. The focus was less on what could be done and more on what should be done, given the disease, the patient, and the realities of delivering these therapies at scale.
Cell and gene therapy feels like it is entering a more mature phase. Success is increasingly defined by fit, safety, manufacturability, and real patient impact. Listening to builders talk openly about constraints and choices was a reminder that progress in this space comes from careful work, not grand claims.
That perspective is what made this discussion worth paying attention to.
Leave a Reply